Abrocitinib, an oral JAK1 inhibitor, that curtails the signaling of IL-4 and IL-13, has been reported to provide early itch symptom relief in the atopic dermatitis (Table 3) [199,200]. This evidence concerns the gene IL4 and atopic eczema.